{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:11:06Z","timestamp":1783379466909,"version":"3.54.6"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1023\/b:brea.0000041586.64371.88","type":"journal-article","created":{"date-parts":[[2004,9,17]],"date-time":"2004-09-17T17:09:53Z","timestamp":1095440993000},"page":"97-107","source":"Crossref","is-referenced-by-count":38,"title":["The Experimental Antitumor Agents Phortress and Doxorubicin are Equiactive Against Human-Derived Breast Carcinoma Xenograft Models"],"prefix":"10.1007","volume":"87","author":[{"given":"Iduna","family":"Fichtner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Monks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm F.G.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracey D.","family":"Bradshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"5274919_CR1","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/sj.bjc.6600225","volume":"86","author":"TD Bradshaw","year":"2002","unstructured":"Bradshaw TD, Chua M-S, Browne HL, Trapani V, Sausville EA, Stevens MFG: In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methyl-phenyl)benzothiazoles. Brit J Cancer 86: 1348\u20131354, 2002","journal-title":"Brit J Cancer"},{"key":"5274919_CR2","first-page":"239","volume":"1","author":"TD Bradshaw","year":"2002","unstructured":"Bradshaw TD, Fichtner I, Bibby MJ, Double JA, Cooper PA, Alley MC, Tomaszewjski JE, Donahue S, Stinson SF, Sausville EA, Stevens MFG: Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Can Therapeutics 1: 239\u2013246, 2002","journal-title":"Mol Can Therapeutics"},{"key":"5274919_CR3","unstructured":"Alley MC, Stinson SF, Pacula-Cox CM, Upadhyay KB, Bradshaw TD, Chua M-S, Stevens MFG, Sausville E: A. Pharmacologic evaluations of fluorinated 2-(4-aminophe-nyl)benzothiazole analogs with unique anticancer activities. Proc AACR 44: #5166, 2000"},{"key":"5274919_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1124\/mol.61.1.13","volume":"61","author":"AI Loaiza-Perez","year":"2002","unstructured":"Loaiza-Perez AI, Trapani V, Hose C, Singh SS, Trepel J, Stevens MFG, Bradshaw TD, Sausville EA: The AhR mediates sensitivity of MCF-7 breast cancer cells to the antitumor agent 2-(4-amino-3-methylphenyl)benzothiazole. Molecular Pharmacol 61: 13\u201319, 2002","journal-title":"Molecular Pharmacol"},{"key":"5274919_CR5","first-page":"5196","volume":"60","author":"M-S Chua","year":"2000","unstructured":"Chua M-S, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, Stevens MFG: Role of CYP1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495)in human breast cancer cells. Cancer Res 60: 5196\u20135203, 2000","journal-title":"Cancer Res"},{"key":"5274919_CR6","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1021\/jm001104n","volume":"44","author":"I Hutchinson","year":"2001","unstructured":"Hutchinson I, Chua M-S, Browne HL, Trapani V, Bradshaw TD, Stevens MFG: Antitumor benzothiazoles. 14. The synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J Med Chem 44: 1446\u20131455, 2001","journal-title":"J Med Chem"},{"key":"5274919_CR7","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1124\/mol.63.3.766","volume":"6","author":"A Monks","year":"2003","unstructured":"Monks A, Harris E, Hose C, Connelly J, Sausville A: Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modi cations underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole. Mol Pharmacol 6: 766\u2013772, 2003","journal-title":"Mol Pharmacol"},{"key":"5274919_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/sj.bjc.6600719","volume":"88","author":"C-O Leong","year":"2003","unstructured":"Leong C-O, Gaskell M, Martin EA, Heydon RT, Farmer PB, Bibby MC, Cooper PA, Double JA, Bradshaw TD, Stevens MFG: Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Brit J Cancer 88: 470\u2013477, 2003","journal-title":"Brit J Cancer"},{"key":"5274919_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0090-9556(25)07309-X","volume":"21","author":"FP Guengerich","year":"1993","unstructured":"Guengerich FP: The Bernard B Brodie award lecture: bioactivation and detoxi cation of toxic and carcinogenic chemicals. Drug Metab Dispos 21: 1\u20136, 1993","journal-title":"Drug Metab Dispos"},{"key":"5274919_CR10","first-page":"49","volume-title":"Basic Environmental Toxicology","author":"LG Hansen","year":"1994","unstructured":"Hansen LG, Shane BS, Xenibiotic metabolism. In: Cockerham LG, Shane BS (eds) Basic Environmental Toxicology, CRC Press, Boca Raton, FL, 1994, pp 49\u2013105"},{"key":"5274919_CR11","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/carcin\/19.11.1969","volume":"19","author":"FG Crofts","year":"1998","unstructured":"Crofts FG, Sutter TR, Strickland PT: Metabolism of 2-amino-1-methyl-6-phenylimidazo [4, 5-b]pyridine by human cytochrome P4501A1, P4501A2 and P4501B1. Carcinogenesis (Lond) 19: 1969\u20131973, 1998","journal-title":"Carcinogenesis (Lond)"},{"key":"5274919_CR12","volume-title":"The Anticancer Drugs","author":"B William","year":"1994","unstructured":"William B, Pratt WB: In: The Anticancer Drugs. 2nd edn. Oxford University Press, New York, 1994","edition":"2nd edn."},{"key":"5274919_CR13","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1021\/jm011025r","volume":"45","author":"I Hutchinson","year":"2002","unstructured":"Hutchinson I, Jennings SA, Vishnuvajjala BR, Westwell AD, Stevens MFG: Antitumor benzothiazoles. 16. Synthesis and pharmaceutical properties of antitumor 2-(4-aminophenyl)benzothiazole amino acid prodrugs. J Med Chem 45: 744\u2013747, 2002","journal-title":"J Med Chem"},{"key":"5274919_CR14","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/jnci\/51.5.1409","volume":"51","author":"HD Soule","year":"1973","unstructured":"Soule HD, Vazquez J, Long A, Albert S, Brennan, M: A human cell line from a pleural effusion derived from a breast carcinoma. JNCI 51: 1409, 1973","journal-title":"JNCI"},{"key":"5274919_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/BF01209485","volume":"119","author":"H Naundorf","year":"1992","unstructured":"Naundorf H, Fichtner I, Buttner B, Frege, J: Establishment and characterization of a new human estradiol-and progesterone-receptor-positive mammary carcinoma serially transplantable in nude mice. J Cancer Res Clin Oncol 119: 35\u201340, 1992","journal-title":"J Cancer Res Clin Oncol"},{"key":"5274919_CR16","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1054\/bjoc.2000.1156","volume":"82","author":"H Naundorf","year":"2000","unstructured":"Naundorf H, Becker M, Lykkesfeldt AE, Elbe B, Neumann C, Buttner B, Fichtner I: Development and characterization of a tamoxifen resistant breast carcinoma xenograft. Brit J Cancer 82: 1844\u20131850, 2000","journal-title":"Brit J Cancer"},{"key":"5274919_CR17","first-page":"129","volume-title":"Immunode cient Animals: Models for Cancer Research","author":"I Fichtner","year":"1996","unstructured":"Fichtner I, Naundorf H, Saul GJ, Zschiesche W, Zeisig R: Establishment and characterization of human xenotransplanted breast carcinoma lines: use for the screening of alkylphosphocholines (APC). In: Arnold W, Kopf-Maier P, Micheel B (eds) Immunode cient Animals: Models for Cancer Research. Contrib Oncol Basel, Karger 51: 129\u2013133, 1996"},{"key":"5274919_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF00665769","volume":"32","author":"H Naundorf","year":"1994","unstructured":"Naundorf H, Fichtner I, Elbe B, Saul GJ, Haensch W, Zschiesche W, Reinecke S: Establishment and characteristics of two new human mammary carcinoma lines in nude mice with special reference to the estradiol receptor status and the importance of stroma for in vivo and in vitro growth. Breast Cancer Res Treat 32: 187\u2013196, 1994","journal-title":"Breast Cancer Res Treat"},{"key":"5274919_CR19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/BF01215983","volume":"119","author":"H Naundorf","year":"1993","unstructured":"Naundorf H, Fichtner I, Saul GJ, Haensch W, Buttner, B: Establishment and characteristics of two new human mammary carcinoma lines serially transplantable in nude mice. J Cancer Res Clin Oncol 119: 652\u2013656, 1993","journal-title":"J Cancer Res Clin Oncol"},{"key":"5274919_CR20","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1021\/jm9600959","volume":"39","author":"D-F Shi","year":"1996","unstructured":"Shi D-F, Bradshaw TD, Wrigley S, McCall CJ, Lelieveld P, Fichtner I, Stevens MFG: Antitumor Benzothiazoles. 3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo. J Med Chem 39: 3375\u20133384, 1996","journal-title":"J Med Chem"},{"key":"5274919_CR21","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/bjc.1998.122","volume":"77","author":"TD Bradshaw","year":"1998","unstructured":"Bradshaw TD, Wrigley S, Shi D-F, Schultz RJ, Paull KD, Stevens MFG: 2-(4-Aminophenyl)benzothiazoles: novel agents with selective pro les of in vitro and in vivo activity. Brit J Cancer 77: 745\u2013752, 1998","journal-title":"Brit J Cancer"},{"key":"5274919_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1054\/bjoc.2000.1231","volume":"83","author":"TD Bradshaw","year":"2000","unstructured":"Bradshaw TD, Chua M-S, Orr S, Matthews CS, Stevens, MFG: Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445). Brit J Cancer 83: 270\u2013277, 2000","journal-title":"Brit J Cancer"},{"key":"5274919_CR23","first-page":"1265","volume":"2","author":"C Hose","year":"2003","unstructured":"Hose C, Hollingshead M, Sausville EA, Monks A: Induction of CYP1A1 in tumor cells by the antitumor agent 2-(4-amino-3-methyl)-5-. uorobenzothiazole: a potential surrogate marker for patient sensitivity. Mol Can Therapeutics 2: 1265\u20131272, 2003","journal-title":"Mol Can Therapeutics"},{"key":"5274919_CR24","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1210\/mend-2-10-886","volume":"2","author":"PJ Vickers","year":"1988","unstructured":"Vickers PJ, Dickens RB, Shoemaker R, Cowan KH: A multidrug-resistant MCF-7 human breast cancer cell line which exhibits cross resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol Endocrinol 2: 886\u2013892, 1988","journal-title":"Mol Endocrinol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/B:BREA.0000041586.64371.88.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/B:BREA.0000041586.64371.88\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1023\/B:BREA.0000041586.64371.88","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/B:BREA.0000041586.64371.88.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T23:46:13Z","timestamp":1750895173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/B:BREA.0000041586.64371.88"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["5274919"],"URL":"https:\/\/doi.org\/10.1023\/b:brea.0000041586.64371.88","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}